|
EMERGING GROWTH ALERT |
|
Issue: 108006 |
August 2005 |
Worldwide Biotech & Pharmaceutical Co
Rapid Growth Alert |
|
Symbol: |
WWBP |
| 52 Week
Range |
2.00 - 11.00 |
| Shares
Float: |
25,000,000 |
| Current
Price: |
$3.73 |
| 12
Mo.Target Price |
$22.00 |
| Growth
Rating |
High |
|
Breaking News Alerts!
Up
0.73
(24.33%) On Friday Alone
Get In While You Still Can!
Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'
Thursday August 25, 9:00 am ET
Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''
ADVERTISEMENT
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''
About World Intellectual Property
Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.
About Worldwide Biotech & Pharmaceutical
Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.
|
Net cash used in investing activities for the three months ended March 31, 2005 was $264,661 as compared to net cash used in investing activities for the three months ended March 31, 2004 of $281,863. For the three months ended March 31, 2005, we used cash for capital expenditures of $264,661. For the three months ended March 31, 2004, we used cash for capital expenditures of $402,782 offset by cash provided from the sale of marketable securities of $120,919. Net cash provided by financing activities for the three months ended March 31, 2005 was $224,591 as compared to net cash used in financing activities for the three months ended March 31, 2004 of $555. For the three months ended March 31, 2005, we received net proceeds of $238,092 from related party advances offset by the repayment of loans and mortgages payable of $13,501.
For the six months ended June 30, 2005, we recorded other income of $43,791 as compared to $0 for the six months ended June 30, 2004 due to the receipt of government subsidiaries.
Item 2. Managements Discussion and Analysis or Plan of Operation (continued) |
|